BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

被引：46
|
作者：
Ribas, A.
Kim, K. B.
Schuchter, L. M.
Gonzalez, R.
Pavlick, A. C.
Weber, J. S.
McArthur, G. A.
Hutson, T. E.
Flaherty, K. T.
Moschos, S. J.
Lawrence, D. P.
Hersey, P.
Kefford, R. F.
Chmielowski, B.
Puzanov, I.
Li, J.
Nolop, K. B.
Lee, R. J.
Joe, A. K.
Sosman, J. A.
机构：
[1] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Penn, Philadelphia, PA 19104 USA
[4] Univ Colorado Hosp, Aurora, CO USA
[5] NYU, Ctr Canc, New York, NY USA
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[7] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[8] Baylor Sammons Canc Ctr Texas Oncol PA, Dallas, TX USA
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[11] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[12] Calvary Mater Hosp, Newcastle, NSW, Australia
[13] Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Melanoma Inst Australia, Sydney, NSW 2006, Australia
[14] Univ Calif Los Angeles, Los Angeles, CA USA
[15] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[16] Roche, Nutley, NJ USA
[17] Plexxikon Inc, Berkeley, CA USA
[18] Hoffmann La Roche Inc, Pharma Res & Early Dev, Nutley, NJ 07110 USA
[19] Hoffmann La Roche AG, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.8509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8509
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma
    Grippo, J. F.
    Zhang, W.
    Heinzmann, D.
    Yang, K. H.
    Wong, J.
    Joe, A. K.
    Munster, P.
    Sarapa, N.
    Daud, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 103 - 111
  • [2] Vemurafenib in Patients With BRAF V600E Mutation-Positive Advanced Melanoma
    Ravnan, Marcus C.
    Matalka, Mazen S.
    CLINICAL THERAPEUTICS, 2012, 34 (07) : 1474 - 1486
  • [3] Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma
    Larkin, James M. G.
    Del Vecchio, Michele
    Ascierto, Paolo Antonio
    Schachter, Jacob
    Garbe, Claus
    Neyns, Bart
    Mandala, Mario
    Lorigan, Paul
    Miller, Wilson H.
    Guminski, Alexander David
    Berking, Carola
    Rutkowski, Piotr
    Queirolo, Paola
    Hauschild, Axel
    Arance, Ana Maria
    Brown, Michael Paul
    Mitchell, Lada
    Veronese, Maria Luisa
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
    Si, Lu
    Zhang, Xiaoshi
    Xu, Zhen
    Jiang, Qiudi
    Bu, Lilian
    Wang, Xuan
    Mao, Lili
    Zhang, Weijiang
    Richie, Nicole
    Guo, Jun
    BMC CANCER, 2018, 18
  • [5] Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
    Andrea P Sponghini
    David Rondonotti
    Marco Giavarra
    Roberto Giorgione
    Francesca Platini
    Journal of Translational Medicine, 13 (Suppl 1)
  • [6] BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma
    Chisholm, Julia C.
    Suvada, Jozef
    Dunkel, Ira J.
    Casanova, Michela
    Zhang, Weijiang
    Ritchie, Natasha
    Choi, YounJeong
    Park, Jane
    Das Thakur, Meghna
    Simko, Stephen
    Tam, Nga Wan Rachel
    Ferrari, Andrea
    PEDIATRIC BLOOD & CANCER, 2018, 65 (05)
  • [7] CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma.
    Ribas, Antoni
    Hodi, F. Stephen
    Kurland, John F.
    Shahabi, Vafa
    Francis, Stephen
    Konto, Cyril
    Joe, Andrew K.
    Lainas, Ioannis
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Cutaneous adverse events associated with vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma: an observational study of 30 treated patients and presentation of a management algorithm
    Sinha, R.
    Edmonds, K.
    Newton-Bishop, J. A.
    Gore, M.
    Larkin, J.
    Fearfield, L. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 9 - 10
  • [9] Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
    Lu Si
    Xiaoshi Zhang
    Zhen Xu
    Qiudi Jiang
    Lilian Bu
    Xuan Wang
    Lili Mao
    Weijiang Zhang
    Nicole Richie
    Jun Guo
    BMC Cancer, 18
  • [10] A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAFV600E mutation-positive metastatic melanoma
    J. F. Grippo
    W. Zhang
    D. Heinzmann
    K. H. Yang
    J. Wong
    A. K. Joe
    P. Munster
    N. Sarapa
    A. Daud
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 103 - 111
12345